Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Dupixent has received regulatory approvals in more than 60 countries in one or more indications

  60% confidence

• More than 1.4 million patients are being treated with Dupixent globally

  60% confidence

• Dupilumab has been studied across more than 60 clinical studies involving more than 12,000 patients with various chronic diseases driven in part by type 2 inflammation

  60% confidence

• Bullous pemphigoid is the seventh approved indication for Dupixent in Japan

  60% confidence

• Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant

  60% confidence

• IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases

  60% confidence

• More than four times as many patients on Dupixent experienced sustained disease remission compared to placebo (18% vs. 4%; p=0.0250) at Week 36

  60% confidence

• BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions

  60% confidence

• Treatment-related adverse events occurred in 26% of Dupixent patients and 15% of placebo patients, with conjunctivitis being the most commonly reported treatment-related AE with Dupixent at 4%

  60% confidence

• Dupixent is approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

  60% confidence

Cited in these Via News reports

• Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →